Rotavirus Prophylaxis Market Report 2026

Rotavirus Prophylaxis Market Overview

• Rotavirus Prophylaxis market size has reached to $9.94 billion in 2025 • Expected to grow to $16.07 billion in 2030 at a compound annual growth rate (CAGR) of 10.3% • Growth Driver: Institutional Funding Drives Growth In The Rotavirus Prophylaxis Market • Market Trend: Next-Generation Multivalent Vaccine Innovations Expanding Protection Against Diverse Rotavirus Strains • North America was the largest region in 2025.

What Is Covered Under Rotavirus Prophylaxis Market?

Rotavirus prophylaxis refers to the prevention of rotavirus infection through vaccination, which protects infants and young children from a highly infectious illness that causes stomach and bowel inflammation. The purpose is to protect from person from any severity. The main types of treatment for rotavirus prophylaxis are rotarix, rotavac, rotavin-m1, oral rehydration fluid and others. Rotavirus is a virus that causes severe stomach or intestinal sickness such as fever, vomiting and diarrhea. The various routes of administration are oral, parenteral and others channeled through hospital pharmacy, retail pharmacy, online pharmacy and others. The end users are hospitals, specialty clinics, home care and others.

What Is The Rotavirus Prophylaxis Market Growth Forecast?

The rotavirus prophylaxis market size is expected to see rapid growth in the next few years. It will grow to $16.07 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to increasing focus on universal vaccine coverage, rising investments in pediatric vaccine development, expansion of vaccination programs in emerging economies, growing demand for affordable vaccine formulations, strengthening of immunization infrastructure. Major trends in the forecast period include increasing expansion of national immunization programs, rising adoption of oral rotavirus vaccines, growing focus on pediatric preventive healthcare, enhanced cold-chain distribution management, expansion of public-private vaccination initiatives.

Global Rotavirus Prophylaxis Market Segmentation

1) By Treatment: Rotarix, Rotavac, Rotavin-M1, Oral Rehydration Fluid, Other Treatments 2) By Route of Administration: Oral, Other Route of Administrations 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels 4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users Subsegments: 1) By Rotarix: Single Dose, Multi-Dose 2) By Rotavac: Liquid Formulation, Freeze-Dried Formulation 3) By Rotavin-M1: Liquid Formulation, Freeze-Dried Formulation 4) By Oral Rehydration Fluid: Electrolyte Solutions, Glucose-Based Solutions 5) By Other Treatments: Supportive Care, Antidiarrheal Medications

What Is The Driver Of The Rotavirus Prophylaxis Market?

Funding from institutions is expected to propel the growth of rotavirus prophylaxis market. Funding from institutions refers to the provision of resources in the form of money, effort, or time, to finance a need, program, or project. Rotavirus’ increasing cases attracted funding from government and private organizations. This funding provides financial and technical assistance across different development phases of rotavirus vaccine and oral medication. For instance, in April 2025, according to the American Medical Association, a US-based professional association for physicians, health spending in the U.S. increased by 7.5% in 2023 to $4.9 trillion or $14,570 per capita. Therefore, increasing the availability of funding will boost the rotavirus prophylaxis industry.

Key Players In The Global Rotavirus Prophylaxis Market

Major companies operating in the rotavirus prophylaxis market are Merck And Co, GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute Of India Pvt Ltd, Zydus Lifesciences Ltd, Sinovac Biotech Ltd, Hualan Biological Engineering Inc, Biological E Limited, PT Bio Farma, Panacea Biotec Ltd, Shanghai Institute Of Biological Products, Wuhan Institute Of Biological Products, Lanzhou Institute Of Biological Products, Changchun Institute Of Biological Products, Beijing Institute Of Biological Products, Shenzhen Kangtai Biological Products Co Ltd, Minhai Biotechnology Co Ltd, CanSino Biologics Inc, Bharat Serums And Vaccines Limited, Walvax Biotechnology Co Ltd, Clover Biopharmaceuticals Ltd, SK Bioscience Co Ltd

Global Rotavirus Prophylaxis Market Trends and Insights

Major companies operating in the rotavirus prophylaxis market are focusing on technological advancements, such as reassortant hexavalent oral vaccines, to meet the rising demand driven by the need for broader serotype coverage and enhanced protection against diverse rotavirus strains prevalent globally. Reassortant hexavalent vaccines are developed using advanced viral reassortment technology to target six dominant rotavirus serotypes (G1, G2, G3, G4, G9, and P1A), thereby providing broad-spectrum protection superior to traditional monovalent or pentavalent vaccines. For instance, in March 2024, Sinovac Biotech Ltd., a China-based biopharmaceutical company, initiated Phase 1 clinical trials for its live, oral reassortant hexavalent rotavirus vaccine, aiming to evaluate safety, tolerability, and immunogenicity across adults, children, and infants. This vaccine’s composition leverages Vero cell technology and aims to generate robust immune responses against multiple strains, addressing changing epidemiology and prevalent serotypes with superior effectiveness. Its innovative approach allows better global immunization coverage, especially in regions where rotavirus shows high genetic diversity.

What Are Latest Mergers And Acquisitions In The Rotavirus Prophylaxis Market?

In June 2024, Murdoch Children’s Research Institute (MCRI), an Australia‑based child‑health research institute, partnered with Incepta Pharmaceuticals for their RV3‑BB rotavirus vaccine to expand access to its neonatal/infant rotavirus vaccine in high‑burden regions by leveraging Incepta’s manufacturing capacity and market reach. Incepta Pharmaceuticals is a Bangladesh-based leading pharmaceutical company that develops, manufactures, and distributes a broad range of vaccines and pharmaceutical products.

Regional Outlook

North America was the largest region in the rotavirus prophylaxis market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Rotavirus Prophylaxis Market?

The rotavirus prophylaxis market consists of revenues earned by entities by providing services such as vaccination, clinical management, awareness programs and diagnosis. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Rotavirus Prophylaxis Market Report 2026?

The rotavirus prophylaxis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the rotavirus prophylaxis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.